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Abstract
Background: Prolactin is secreted from the pituitary gland and other organs, as well as by cells such as
lymphocytes. Prolactin has an immunostimulatory effect and is associated with autoimmune diseases that are
characterised by abnormal B cell activation, such as systemic lupus erythematosus (SLE). Our aim was to determine
if different splenic B cell subsets express the prolactin receptor and if the presence of prolactin influences these B
cell subsets and correlates with development of lupus.
Results: Using real-time PCR and flow cytometry, we found that different subsets of immature (transitional) and
mature (follicular, marginal zone) B cells express different levels of the prolactin receptor and are differentially
affected by hyperprolactinaemia. We found that transitional B cells express the prolactin receptor at higher levels
compared to mature B cells in C57BL/6 mice and the lupus-prone MRL/lpr and MRL mouse strains. Transitional-1
(T1) B cells showed a higher level of prolactin receptor expression in both MRL/lpr and MRL mice compared to
C57BL/6 mice. Hyperprolactinaemia was induced using metoclopramide, which resulted in the development of
early symptoms of SLE. We found that T1 B cells are the main targets of prolactin and that prolactin augments the
absolute number of T1 B cells, which reflects the finding that this B cell subpopulation expresses the highest level
of the prolactin receptor.
Conclusions: We found that all B cell subsets express the prolactin receptor but that transitional B cells showed
the highest prolactin receptor expression levels. Hyperprolactinaemia in mice susceptible to lupus accelerated the
disease and increased the absolute numbers of T1 and T3 B cells but not of mature B cells, suggesting a primary
effect of prolactin on the early stages of B cell maturation in the spleen and a role of prolactin in B cell
differentiation, contributing to SLE onset.
Background
Prolactin (PRL) is a lactogenic hormone that is mainly
produced by the anterior pituitary gland. PRL has multi-
ple functions that regulate reproduction, development
and growth, osmosis, metabolism of carbohydrates and
lipids and the immune system. Each of these functions
requires expression of the PRL receptor in different
extra-pituitary regions [1]. In the immune system, inter-
action between hormones and receptors activates the
transcription of genes involved in different cellular func-
tions, such as proliferation, differentiation, and cytokine
production [2-4]. PRL has been implicated as a modula-
tor of both cellular and humoral immunity [1-4].
Elevated serum levels of PRL have been reported in
several autoimmune diseases, including multiple sclero-
sis [5] and systemic lupus erythematosus (SLE) [6-9],
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diseases such as autoimmunity during chronic hepatitis
C [10]. Moreover, women with hyperprolactinaemia but
without autoimmune disorders have been reported to
have circulating autoantibodies [11].
SLE is an autoimmune rheumatic disease. Serum sam-
ples from SLE patients characteristically have very strong
reactivity to a broad spectrum of nuclear components,
including DNA, RNA, histones, RNP, Ro, and La. These
antibodies form immune complexes that are deposited in
the kidneys and may cause proteinuria and kidney failure.
The presence of these autoantibodies indicates abnormal-
ities in the activation and development of B cells [12,13],
and both B and T cells express the PRL receptor and pro-
duce and secrete PRL [1,14-16]. SLE mainly affects
women of the reproductive age at a ratio of 9:1 compared
to men, and this gender bias has been attributed to the
immunostimulatory properties of hormones. SLE symp-
toms tend to start or become exacerbated during preg-
nancy, when serum PRL levels are high. High serum
concentrations of PRL correlate with SLE activity [6-8],
and hyperprolactinaemic patients with antiphospholipid
syndrome display significantly more serositis and peritoni-
tis compared to healthy individuals. [9,17]. These findings
have also been observed in the murine NZB × NZW
model of lupus after the induction of hyperprolactinaemia,
in which the presence of PRL correlates with the early
detection of immune complexes, proteinuria, and acceler-
ated death [18].
MRL-MpJFas
lpr (MRL/lpr) mice have a mutation in
the Fas gene and develop a disease similar to SLE, char-
acterised by glomerulonephritis, vasculitis, splenomegaly,
hypergammaglobulinemia and the production of anti-
dsDNA antibodies [19]. In this strain of mouse, elimi-
nating B cells using an anti-CD79 antibody decreased
manifestations of the SLE-like disease, demonstrating
the importance of B cells in SLE physiopathology
[20,21]. B cells start their maturation process in the
bone marrow, undergoing the proB, preB and immature
stages, and finish maturation in the spleen, where the
transitional and mature B cell subsets can be found.
These populations are distinguished by the expression
of different surface molecules. Allman et al. classified
transitional B cells into three types: transitional-1 (T1
[CD93
+,I g M
high,C D 2 3
-]), transitional-2 (T2 [CD93
+,
IgM
high,C D 2 3
+]), and transitional-3 (T3 [CD93
+,
IgM
low,C D 2 3
+]), while mature B cells are classified as
follicular (FO [CD93
-,C D 2 1
int,C D 2 3
high]) or marginal
zone (MZ [CD93
-, CD21
high, CD23
-]) [22].
The objective of this study was to determine whether
different splenic B cell subsets express the PRL receptor
and if the presence of PRL influences these B cells sub-
sets and correlates with the development of lupus. We
found that all B cell subsets expressed the PRL receptor
but that transitional B cells displayed higher expression
levels compared to mature B cells. Hyperprolactinaemia
in mice susceptible to lupus accelerated the disease and
increased the absolute numbers of T1 and T3 B cells
but not mature B cells, suggesting that PRL participates
in the early stages of splenic B cell development.
Results
Expression of the PRL receptor varies among the different
splenic B cell subsets
The follicular, marginal zone, and transitional splenic B
cell subsets were purified from C57BL/6 wild-type mice
by flow cytometry with greater than 95% purity (Figure
1 )a n dw e r ea s s a y e df o rt h ee x p r e s s i o no ft h eP R L
receptor at the mRNA and protein levels. We found
that splenic B cells expressed the PRL receptor, with
transitional B cells showing the highest relative mRNA
expression (13.6 ± 0.2). Among the mature B cells sub-
sets, MZ B cells showed approximately two-fold higher
expression (9.3 ± 0.8) than the FO B cells (5 ± 0.3) (Fig-
ure 2A). At the protein level, we found that transitional
B cells expressed the highest level of the PRL receptor
(283.3 ± 52.4 MFI [mean fluorescence intensity]), fol-
lowed by MZ B cells (173.0 ± 18.6 MFI) and FO B cells
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Figure 1 Purification of B cell subsets by flow cytometry. B cells
were purified by negative selection from 9-week-old mice. Splenic
cells were incubated with different antibodies (anti-CD19, anti-CD93,
anti-CD21, anti-CD23, and anti-IgM), and the different B cell subsets
were purified by flow cytometry as detailed in the Methods section.
The purity of the collected populations oscillated between 95% and
98%. A representative example of the purified B cells from wild-type
C57BL/6 mice is shown.
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Page 2 of 14(103.0 ± 16.0 MFI), similar to the pattern observed with
PRL receptor mRNA expression (Figure 2B and 2C).
Within the transitional subset, T2 B cells showed the
highest protein levels of the PRL receptor (458.7 ±
92.5), followed by T1 (225.2 ± 32.3) and T3 (208.7 ±
59.4) B cells (Figure 2D).
When the protein level of PRL receptor among total
splenic B cells from C57BL/6 wild-type mice was com-
pared with that in the lupus-prone MRL and MRL/lpr
mice, we found a statistically significant (p < 0.05)
increase in PRL receptor expression in the MRL mice
(two-fold increase; 237.0 ± 93.8 MFI) and in the MRL/
lpr mice (three-fold increase; 306.3 ± 58.1 MFI) than in
the C57BL/6 mice (96.7 ± 16.6 MFI). The differences in
PRL receptor expression between MRL and MRL/lpr
mice were also statistically significant (p < 0.05) (Figure
3A).
When individual B cell subsets were evaluated, we
observed a statistically significant increase (p < 0.05) in
PRL receptor protein expression in FO B cells from
MRL/lpr mice (238.0 ± 63.5 MFI) compared to that in
cells from C57BL/6 mice (111.2 ± 39.0 MFI). PRL recep-
tor expression in MRL mice was only slightly elevated
compared to that in C57BL/6 mice. In MZ B cells, there
was not a statistically significant difference in PRL
receptor protein expression between C57BL/6, MRL and
MRL/lpr mice (190.5 ± 17.6, 201.4 ± 59.1 and 266.0 ±
71.9 MFI, respectively). A statistically significant differ-
ence in receptor expression was observed in transitional
B cells, with MFI of 805.5 ± 64.6 in the MRL/lpr strain,
437.5 ± 82.6 in MRL strain and 283.5 ± 41.3 in the
C57BL/6 mice (Figure 3B). Among the transitional B
cell subsets, T1 cells displayed the greatest levels of PRL
receptor protein expression in MRL/lpr (1105.7 ± 79.9
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Figure 2 Expression of prolactin receptor in different subsets of splenic B cells from C57BL/6 mice. The different B cell subsets from 9-
week-old C57BL/6 mice were purified by flow cytometry in four independent experiments using eight mice per experiment. Using real-time
PCR, PRL receptor (PRL-R) mRNA expression was determined in the following different subsets of splenic B cells: A) Follicular (FO), marginal zone
(MZ), and transitional (T). The protein expression levels of the PRL receptor were determined for ten mice of each strain by flow cytometry, and
the mean fluorescence intensity (MFI) is shown in the following B cell subsets: B) Follicular; marginal zone; and transitional. C) Histograms of PRL
receptor expression in the different subsets of B cells are shown. D) Transitional 1, 2 and 3. The asterisks denote statistical significance with the p
value shown.
Ledesma-Soto et al. BMC Immunology 2012, 13:11
http://www.biomedcentral.com/1471-2172/13/11
Page 3 of 14MFI) and MRL (749.0 ± 78.0 MFI) mice but not in
C57BL/6 (225.5 ± 32.3 MFI) mice. We found similar
levels of PRL receptor expression in T2 cells from MRL/
lpr (640.0 ± 59.0 MFI), MRL (551.3 ± 75.5 MFI) and
C57BL/6 (482.8 ± 159.0 MFI) mice, while T3 cells from
the MRL/lpr mice showed the highest level (365.8 ±
43.7 MFI), followed by MRL (310.4 ± 56.8 MFI) and
C57BL/6 mice (206.6 ± 94.3 MFI). Of all the splenic B
cell subsets, T1 cells from the MRL/lpr strain displayed
the highest expression of the PRL receptor (Figure 3C).
Induction of hyperprolactinaemia results in an early onset
of SLE in the disease-prone MRL/lpr and MRL mice and
correlates with the increased expression of the PRL
receptor in transitional B cells
Nine-week-old MRL/lpr, MRL and C57BL/6 mice were
treated with metoclopramide for six weeks to induce
high levels of PRL in the serum before testing for accel-
erated SLE symptoms. The serum concentration of PRL
in the C56BL/6 strain was 0.8 ± 0.4 ng/ml before treat-
ment and 1.4 ± 0.9 ng/ml when treated with PBS, while
mice treated with metoclopramide showed PRL concen-
trations that were 10-fold higher than those before
treatment (8.1 ± 0.9 ng/ml). In the MRL mice, the
serum PRL concentration was 12.5 ± 1.9 ng/ml before
treatment, 11.2 ± 1.8 ng/ml when treated with PBS, and
26.2 ± 2.7 ng/ml after being treated with metoclopra-
mide. In MRL/lpr mice, the serum PRL concentration
was 9.1 ± 2.4 ng/ml, and this concentration increased to
15.4 ± 2.7 ng/ml in mice treated with PBS and to 29.6 ±
5.3 ng/ml in mice treated with metoclopramide.
Although an increase in the PRL concentration was
observed in the MRL/lpr mice treated with PBS (mice at
15 weeks of age), this increase did not reach the levels
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Figure 3 Expression of prolactin receptor in C57BL/6 wild-type, MRL and MRL/lpr lupus-prone mice. Protein expression of the PRL
receptor (PRL-R) was determined by flow cytometry (MFI) from 14 C57BL/6 and MRL/lpr mice and 7 MRL mice. Splenocytes were marked with
anti-CD19, anti-CD93, anti-IgM, anti-CD21, anti-CD23, and goat anti-PRL receptor A) splenic B cells; B) Follicular (FO), marginal zone (MZ),
transitional B cells; and C) Transitional 1, 2 and 3. Asterisks denote statistical significance with the p value shown.
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Page 4 of 14observed in animals treated with metoclopramide (Fig-
ure 4A). The consistent increase in the serum concen-
tration of PRL in metoclopramide-treated mice was
considered to constitute hyperprolactinaemia and corre-
lated with the premature onset of disease symptoms in
lupus-prone mice (see below).
Lupus manifestations were compared in all mouse
strains before and after metoclopramide and PBS treat-
ments. The MRL/lpr mice treated with PBS developed
proteinuria (50.8 ± 15.7 mg/dl), constituting a significant
increase compared to the beginning of the treatment
(12.5 ± 4.6 mg/dl). MRL/lpr mice treated with metoclo-
pramide showed a greater increase in proteinuria (104.3
± 30.7 mg/dl). By comparison, MRL mice developed
proteinuria after metoclopramide treatment (118.5 ±
37.4 mg/dl) but not PBS treatment. Metoclopramide-
treated, PBS-treated and untreated mice were tested for
serum concentrations of anti-dsDNA antibodies of the
IgG isotype. A significant increase in anti-dsDNA anti-
bodies was observed in hyperprolactinaemic MRL/lpr
mice (16.0 ± 2.9 μg/ml) compared to mice treated with
PBS (9.5 ± 1.6 μg/ml) and the levels found at the
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Figure 4 SLE manifestations in mice with hyperprolactinaemia. Fourteen C57BL/6 and MRL/lpr mice, and seven MRL mice at 9 weeks of age
were treated for 6 weeks with metoclopramide (100 μg/100 μl) or PBS (100 μl). At the end of the treatment, the following measurements were
taken: A) PRL concentration by ELISA; B) level of proteinuria using reactive strips; C) anti-dsDNA IgG antibodies; and D) anti-dsDNA antibodies of
the IgG1 and IgG2a isotypes in the MRL and MLR/lpr mice by ELISA. The asterisks denote statistical significance between groups with the p
value shown. HyperPRL = Hyperprolactinaemic
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Page 5 of 14beginning of the treatment (1.3 ± 0.5 μg/ml). At the
beginning of treatment in MRL mice, we did not detect
the presence of anti-dsDNA antibodies. However, we
observed low concentrations of anti-dsDNA antibodies
after PBS treatment (3.2 ± 1.8 μg/ml), and these concen-
trations increased significantly in hyperprolactinaemic
mice (15.1 ± 5.6 μg/ml). The C57BL/6 mice did not
develop proteinuria after PBS or metoclopramide treat-
ment, and we did not detect anti-dsDNA antibodies
under any condition studied (Figure 4B and C). The
main antibody isotypes found in both lupus-prone
strains were IgG2a and, to a lesser degree, IgG1 (Figure
4D). No statistically significant differences were found in
the production of anti-dsDNA antibodies of the IgM
isotype (data not shown). Taken together, these data
indicate that metoclopramide treatment induces hyper-
prolactinaemia and that this state was associated with
early manifestations of SLE in the lupus-prone MRL and
MRL/lpr mice.
Next, we tested PRL receptor expression in whole
splenic B cell populations from the hyperprolactinaemic
and PBS-treated control mice. However, we did not find
any differences in PRL receptor expression in C57BL/6
mice regardless of age or treatment. In contrast, we
found that MRL/lpr mice with hyperprolactinaemia
showed a significant increased by more than two-fold in
PRL receptor expression compared to mice treated with
PBS. Therefore, hyperprolactinaemia correlated with
upregulation of the PRL receptor in splenic B cell popu-
lations. Interestingly, in the MRL/lpr lupus-prone mice,
the normal manifestations of SLE occur at 25 weeks of
age. When we compared PRL receptor expression in
splenic B cells from hyperprolactinaemic mice (15 weeks
of age) and untreated diseased mice (25 weeks of age),
no differences were found. We found no differences in
PRL receptor expression between the C57BL/6 and
MRL/lpr strains at 9 weeks of age. In contrast, there
was a statistically significant increase in PRL receptor
expression in MRL/lpr mice at 15 and 25 weeks of age
(p < 0.05) (Figure 5).
During hyperprolactinaemia, there was a significant
increase in PRL receptor expression in MRL/lpr and
M R Lm i c eb u tn o ti nC 5 6 B L / 6m i c e( F i g u r e6 A ) .I n
addition, correlating with the expression patterns of the
PRL receptor in non-hyperprolactinaemic conditions
(Figure 3), transitional B cells seemed to be the main
cells responding to the high levels of PRL by further
increasing expression of the PRL receptor. Of the transi-
tional B cells, T1 B cells were the population with the
highest increase in PRL receptor expression levels in
MRL/lpr [1105.7 ± 79.9 (9 weeks) vs. 1650.2 ± 232.4
MFI (hyperprolactinaemia)] and MRL mice (749.0 ±
78.0 vs. 3407.2 ± 273.2 MFI), although all transitional B
cell populations displayed increased PRL receptor
expression in the hyperprolactinaemic state in MRL/lpr
[T2 (640.0 ± 59.0 vs. 1266.8 ± 300.9 MFI) and T3 (365.8
± 43.7 vs. 756.0 ± 249.7 MFI)] and MRL [T2 (551.3 ±
75.5 vs. 2938.6 ± 145.1 MFI) and T3 (310.4 ± 56.8 vs.
1251.6 ± 521.6 MFI)] mice (Figures 6B, C). No signifi-
cant changes were observed in the mature splenic B cell
populations. These data suggest a role for PRL in B cell
development, mainly in splenic transitional B cells, that
correlates with premature manifestations of SLE.
MZ, but not FO, B cells are altered in untreated and
hyperprolactinaemic MRL/lpr lupus-prone mice
Given that the greatest level of PRL receptor expression
was found in immature developing splenic B cells, we
evaluated whether PRL influences the absolute number
of these cells. In agreement with a role for PRL in devel-
oping splenic B cells, we found that hyperprolactinaemic
MRL/lpr mice showed an increase in the absolute num-
ber of B cells (158.2 ± 27.2 × 10
6 cells) compared to
untreated mice (82.7 ± 13.19 × 10
6 cells). However, no
significant difference was found in mice treated with
PBS at 15 weeks of age (113.0 ± 29.7 × 10
6 cells). Simi-
larly, hyperprolactinaemic MRL mice showed an
increase in the absolute number of B cells (104.6 ± 21.3
×1 0
6 cells) compared to untreated mice (69.9 ± 4.7 ×
10
6 cells) and PBS-treated mice (59.8 ± 19.1 × 10
6 cells)
(Figure 7A). Due to the different levels of PRL receptor
expression in the different splenic B cells populations,
we analysed each B cell subset individually. Figure 7B
shows the mature MZ and FO B cell pools before and
*
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Figure 5 Prolactin receptor expression in MRL/lpr mice at
different ages. Ten C57BL/6 and ten MRL/lpr mice were treated
with metoclopramide (100 μg/100 μl) for 6 weeks
[hyperprolactinaemia (HyperPRL)] or PBS (control). Splenic B cells
were purified using negative selection from treated and untreated
mice: at 9 and 25 weeks of age (untreated) and 15 weeks of age,
mice were treated with metoclopramide or PBS (expression of the
PRL receptor was determined by real-time PCR [mRNA]). The
asterisks denote statistical significance between populations with
the p value shown.
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Page 6 of 14after metoclopramide and PBS treatment in wild type
C57BL/6, MRL and MRL/lpr mice. When these mature
B cell subsets were quantified, MZ B cells in MRL/lpr
mice showed an increase in absolute numbers that cor-
related with the development of disease 15 weeks of age
compared to 9 week mice (12.5 ± 6.5 × 10
6 and 26.7 ±
4.0 × 10
6 cells, respectively), but no further significant
increases were found in MZ B cells from mice with
hyperprolactinaemia (35.5 ± 16.2 × 10
6 cells). In MRL
mice, we did not observe any differences between mice
9 weeks and those treated with PBS; however, hyperpro-
lactinaemic mice showed an increase in the absolute
number of MZ cells (Figure 7C). No differences in FO B
cell numbers were detected regardless of the mouse
strain or treatment tested (Figure 7D). Similarly, we did
not detect any changes in the absolute numbers of FO
or MZ B cells from C57BL/6 mice (Figures 7C, and 7D).
Prolactin preferentially targets transitional-1 B cells and
increases their absolute numbers in the spleen
The largest difference in the absolute number of splenic
B cell was found in T1 B cells, correlating with the high
level of PRL receptor expression observed in this popu-
lation. Figure 8A displays the transitional populations
and Figure 8B displays the greater than two-fold
increase in the absolute number of T1 B cells in the
hyperprolactinaemic MRL/lpr mice compared to PBS-
treated mice (1.5 ± 0.2 × 10
6 c e l l sa n d0 . 7±0 . 4×1 0
6
cells, respectively). The same phenotype was observed in
MRL mice, in which the absolute number of T1 B cells
only increased in the hyperprolactinaemic mice [1.3 ±
0.1 × 10
6 cells (hyperprolactinaemic) and 0.6 ± 0.10 ×
10
6 cells (PBS)]. In contrast, the absolute number of T2
B cells was not affected by hyperprolactinaemia in any
of the strains, as shown in Figure 8C. Moreover, a small
but significant increase was found in T3 B cells (Figure
8D) from hyperprolactinaemic MRL/lpr mice (0.8 ± 0.3
×1 0
6 cells) and MRL mice (0.6 ± 0.1 × 10
6 cells) com-
pared to that in cells from PBS-treated mice [MRL/lpr
( 0 . 4±0 . 1×1 0
6 c e l l s )a n dM R L( 0 . 3±0 . 1×1 0
6 cells)].
As expected, there were no differences in the absolute
numbers of T1, T2 or T3 B cells between the different
treatment groups in C57BL/6 mice. Taken together,
these data support a role for PRL in B cell development
through the regulation of the size of the T1 B cell pool
in the spleen.
Discussion
Several studies have demonstrated a role for prolactin
(PRL) and B cells in the development of autoimmune
diseases such as systemic lupus erythematosus (SLE)
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Figure 6 Prolactin receptor expression after the induction of
hyperprolactinaemia. The levels of PRL receptor protein in
transitional (T1, T2, and T3) and mature (FO and MZ) B cells were
determined by flow cytometry (MFI). At the end of the treatment,
spleen cells were marked with anti-CD19, anti-CD93, anti-IgM, anti-
CD21, anti-CD23, and goat anti-PRL receptor. A) C57BL/6 mice; B)
MRL mice and C) MRL/lpr mice. The asterisks denote statistical
significance between populations with the p value shown.
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Page 7 of 14[6-9,12,13,18,20,21,23,24]. In this study, we evaluated
how PRL affects the course of SLE development in
MRL/lpr, MRL, and wild-type mice and observed how
this finding correlates with changes in the different sple-
nic B cell subsets. The MRL/lpr strain has a mutation in
the Fas gene and develops a disease similar to SLE [25].
MRL mice also exhibit autoimmune disorders despite
carrying a normal Fas gene, but the symptoms manifest
m u c hl a t e ri nl i f et h a ni nM R L / l p rm i c e[ 1 9 ] .T oo u r
knowledge, this study is the first to address PRL recep-
tor expression in all of the different subsets of splenic B
cells.
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Page 8 of 14Interestingly, expression of the PRL receptor followed
as i m i l a rp a t t e r ni nBc e l l s from wild-type C57BL/6,
SLE-prone MRL/lpr and MRL mice. Expression of the
PRL receptor varied according to the B cell developmen-
tal stage. The highest expression of the PRL receptor
was observed in the immature, transitional splenic B
cells. Our findings are consistent with those reported by
Morales et al. [26], who transfected proB cells with the
PRL receptor triggered their progression to the preB
stage through incubation with PRL. Taken together,
d a t af r o mM o r a l e se ta l .a n do u rg r o u ps u g g e s tt h a t
PRL participates in early B cell differentiation. Our
results showed that the pattern of PRL receptor expres-
sion levels in transitional B cells was different in
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Page 9 of 14C56BL/6 mice and the lupus-prone mouse strains. T2
cells showed higher expression of the PRL receptor in
C7BL/6, while in lupus-prone strains the T1 cells
showed higher expression. These data argue that there
is altered expression of the PRL receptor in different B
cells subsets during the autoimmune process. Further-
more, the differential presence of the receptor in transi-
tional populations in C56BL/6 mice suggests a
regulatory role for PRL in these cells under non-patho-
logical conditions.
Transitional B cells are constantly testing their antigen
receptors (BCR) to identify B cell clones expressing
receptors with self-specificity [27]. These clones then
trigger different intrinsic mechanisms that eliminate this
self-specificity. The MRL strains have a genetic back-
ground prone to develop a disease similar to SLE either
earlier in life in the case of MRL/lpr mice or later in the
case of MRL mice. We found that the T1 B cell subset
in both of these strains had the most PRL receptor pro-
tein expression. Therefore, it is possible that increased
PRL receptor expression at this stage in lupus-prone
strains could promote both the rescue of autoreactive
clones and B cell developmental progression, thus
favouring the development of lupus symptoms. This
observation is in agreement with the fact that PRL
receptor signalling increases the expression of the anti-
apoptotic gene Bcl-2 [28,29] and that T1 B cells from
hyperprolactinaemic ovariectomised BALB/c mice are
more resistant to apoptosis than those from PBS-treated
mice [30]. Future experiments should address the mole-
cular role of PRL in this population and better define its
contribution in autoimmune disease.
C57BL/6, MRL and MRL/lpr mice treated with meto-
clopramide showed a further increase in their serum
PRL levels that was only accompanied by increased
levels of anti-dsDNA antibodies and proteinuria in the
MRL/lpr and MRL lupus-prone strains. These findings
are in agreement with previous reports studying other
hyperprolactinaemic and SLE models, such as reports by
McMurray et al. [18,31] who showed hyperprolactinae-
mia induced by pituitary gland transplantation in NZB ×
NZW mice, and a report by Peeva et al. using recombi-
nant PRL to induce hyperprolactinaemia in Sle3/5 R4A-
g2b C57BL/6 mice [32]. Additionally, our data are con-
sistent with several clinical trials showing that a high
serum PRL level correlated with SLE disease activity
[7,33,34].
In our study, PRL receptor mRNA expression was
increased in metoclopramide-treated 15-week-old MRL/
lpr mice to a level similar to that found in untreated 25-
week-old mice displaying high disease activity. This cor-
relation between PRL receptor levels and the degree of
disease suggests that PRL plays an important role in the
development and exacerbation of SLE. These results
also support the idea that the PRL receptor could be
useful as an SLE prognostic marker.
Although our results showed that the T2 subset of B
cells express the highest levels of the PRL receptor in
the spleens of C57BL/6 mice, the absolute number of
T2 cell and other B cell subsets and overall PRL recep-
tor expression were not affected by hyperprolactinaemia,
and SLE was not induced. This result differs from pre-
vious reports by Peeva et al. and Saha et al. describing
decreased T1 B cell frequencies and increased T2 B cell
frequencies after the induction of hyperprolactinaemia,
w h i l et h eM Za n dF Om a t u r eBc e l lp o o l sw e r eu n a f -
fected [30,35]. This finding may be due to the different
experimental approaches used, in that different mouse
strain was used (BALB/c), BALB/c mice were ovariecto-
mised, a procedure that eliminates oestrogen and pro-
gesterone and affects immune responses [36,37]. In
addition, we treated mice with metoclopramide to
induce the hyperprolactinaemic state, whereas Peeva
and Saha used ovine PRL.
In our study, hyperprolactinaemia resulted in up-regu-
lation of PRL receptor expression and a significant
increase in the absolute numbers of T1 B cells in the
MRL/lpr mice. PBS-treated mice did not show increases
in the absolute number of T1 cells, despite an increase
in PRL receptor expression, we believe that this is
because the level of PRL receptor expression in PBS-
treated mice never reached the levels found in either
pharmacologically induced or age-related hyperprolacti-
naemic mice. Additionally, in the MRL strain, the abso-
lute number of T1 cells only increased in
hyperprolactinaemic mice, correlating with the early
onset of lupus symptoms and increased PRL receptor
expression. A similar observation has been noted in NK
cell lines, in which high PRL receptor expression corre-
lates with an enhanced capacity of the cells to prolifer-
ate [38]. This finding is also in agreement with the
observation that the T1 population expresses the highest
level of PRL receptor expression before treatment and
with other studies showing this subset to be more resis-
tant to apoptosis in mice with hyperprolactinemia [30].
Thus, our data and that of others [30,38,39] support the
importance of PRL in B cell development, in develop-
mental associated processes such as proliferation and
resistance to negative selection and in the progression of
SLE. These findings highlight the idea that this disease
originates at different levels, as indicated by its multifa-
ceted nature.
We also found that hyperprolactinaemia increased the
expression of the PRL receptor and, to a lesser degree,
the absolute numbers of T3 B cells. T3 B cells are con-
sidered by Merrel to be a subset of anergic B cells pro-
duced by the interaction of the BCR and self-antigens
and are not a part of the maturation pathway of B cells
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mice, and this decrease has been proposed to be due to
self-reactive clones escaping from an anergic state in
this mouse strain. This diminished T3 population was
described in 9-week-old mice; however, this time point
is prior to disease onset, and these mice were compared
to the genetically unrelated BALB/c strain [42]. There-
fore, future work should determine the effect, if any, of
PRL signalling in this population and may generate
interesting results.
The number of MZ B cells in MRL/lpr mice increased
with age and coincided with the course of the disease,
as previously reported [43]. Higher levels of serum PRL
induced a further increase in the MZ B cell population,
although this change was not significant when compared
to mice of the same age treated with PBS. However, this
increase in the absolute number of MZ cells was statisti-
cally significant in hyperprolactinaemic-MRL mice.
These results are consistent with a model in which PRL
increases the expression of its receptor mainly in imma-
ture transitional B cells, leading to self-reactive cell
maturation with a potential bias toward the MZ type.
Although PRL did not affect the absolute number of
mature B cells or their PRL receptor expression pattern,
self-reactive clones were more active in hyperprolacti-
naemic MRL/lpr and MRL mice as shown by an
increased concentration of anti-dsDNA antibodies, spe-
cifically of the IgG isotype. It will be interesting to dis-
cern the function of PRL in the MZ and FO mature
populations, as it is clear that they perform different
functions. While MZ B cells are part of the innate
immune system and preferentially respond to T cell-
independent antigens, FO B cells perform the classic
functions of adaptive immunity. MZ B cells have mainly
been associated with the expression of IgM antibodies
[44,45].
Our results show that both MRL/lpr and MRL mice
develop an early onset of lupus symptoms after induc-
tion of hyperprolactinemia. Although the MRL/lpr strain
h a sa na d d i t i o n a lm u t a t i o ni nF a s[ 1 9 , 4 6 ] ,o u rr e s u l t s
also suggest that this genetic change most likely has lit-
tle, if any, effect on the accelerated lupus development.
It is possible that strong PRL signalling in immature T1
B cells from both mice strains could potentially trigger
rescue from apoptosis induced by recognition of self-
antigens and could also shape and promote their differ-
entiation into specific mature B cell populations. The
presence of self-reactive clones in MZ B cells correlates
with autoimmune diseases [47].
Conclusions
O u rd a t as u p p o r tar o l ef o rP R Li nBc e l ld e v e l o p m e n t
by primarily affecting the size of the T1 B cell pool in
the spleen. Although PRL exhibits pleiotropic effects in
different organs, our results are consistent with a prefer-
ential effect in the regulation of the PRL receptor in the
T1 population that is responsible for the observed
altered B cell development and premature onset of SLE
symptoms. Understanding the molecular mechanisms
resulting in the development of SLE will help to design
prevention, treatment and follow-up strategies for this
disease.
Methods
Mice
All studies were approved by the Animal Care Commit-
tee of Instituto Nacional de Ciencias Médicas y Nutri-
ción “Salvador Zubiran” and Hospital de Pediatría,
Centro Médico Nacional Siglo XXI IMSS, and all of the
measurements taken from the mice were in accordance
with approved guidelines established by Mexico (Norma
Oficial Mexicana NOM-062-ZOO-1999) and the NIH
Guide for the Care and Use of Laboratory Animals. The
C57BL/6 mice were purchased from Harlan (Indianapo-
lis, USA), and the MRL/MpJ FAS
lpr (MRL/lpr) and
MRL/MpJ (MRL) mice were purchased from the Jack-
son Laboratory (Maine, USA). All of the mice were
housed in a specific pathogen-free barrier facility and
were provided sterile food and water ad libitum.
Antibodies
The following antibodies were used: anti-mouse CD21-
FITC (7 G6) and CD21-APC (7 G6) were from BD Bios-
ciences (Mountain View CA, USA); CD93-PE (AA4.1),
CD23-biotinylated, IgM-APC (11/41), CD19-Cy7 (1D3),
CD23-PE-Cy7 (B3B4), CD19-FITC (eBioD3), and IgM-
biotinylated (11/41) were from eBioscience (San Diego
CA, USA); goat anti-mouse PRL-R (E20) was from
Santa Cruz Biotechnology (Santa Cruz CA, USA); and
swine anti-goat-biotinylated was from Invitrogen (Carls-
bad CA, USA). The biotinylated secondary antibody was
detected with streptavidin-phycoerythrin-Cy5.5 from BD
Biosciences (Mountain View CA, USA).
Purification of B cells
Single-cell suspensions were prepared from spleens.
After red blood cell lysis with lysing buffer (Sigma
Aldrich, St. Louis Missouri, USA), the cells were incu-
bated with anti-CD43 (Ly-48) microbeads (Miltenyi Bio-
tec, Bergisch Gladbach, Germany) and the B cells were
isolated using negative selection with a magnetic acti-
vated cell-sorting (MACS) system (Miltenyi Biotec, Ber-
gisch Gladbach, Germany). After depletion, > 98% of the
remaining cells were CD19
+ by flow cytometry.
Cell sorting
Single-cell suspensions of B cells were incubated with
fluorescently labelled antibodies specific for CD19,
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with 0.5% BSA) for 20 minutes at 4°C. The cells were
washed, and the B cell (CD19
+) subsets were isolated
according to the expression of the following surface
markers: marginal zone (CD93
-, CD21
high, CD23
-); folli-
cular (CD93
-, CD21
int, CD23
high); transitional-1 (CD93
+,
IgM
high, CD23
-); transitional-2 (CD93
+, IgM
high, CD23
+);
and transitional-3 (CD93
+,I g M
low,C D 2 3
+). Cell sorting
was performed using a FACSAria sorter with FACSDiva
software (BD Bioscience). The purity of the sorted cells
ranged from 95% to 98%.
Real-time PCR
Total RNA was extracted from B cells of C57BL/6 and
MRL/lpr mice using TRIzol reagent (Invitrogen, Carls-
bad CA, USA), according to the manufacturer’sp r o t o -
col, and the RNA concentration was determined using
UV spectrophotometry. Next, 1 μgo ft o t a lR N Aw a s
used to generate cDNA with SuperScript II reverse tran-
scriptase (Invitrogen, Carlsbad CA, USA), according to
the manufacturer’s specifications. The PRL receptor
cDNA was amplified by real-time PCR using a LightCy-
cler TaqMan Master kit (Roche Diagnostic, Mannheim,
Germany), according to manufacturer’s specifications
and using hydrolysis probes and primers designed by
Roche Diagnostic. The following primers were used:
PRL-R 5’-CAGTAAATGCCACGAACGAA-3’ (left);
PRL-R 5’-GAGGAGGCTCTGGTTCAACA-3’ (right); b-
actin 5’-AAGGCCAACCGTGAAAAGAT-3’ (left); and
b-actin 5’-GTGGTACGACCAGAGGCATAC-3’ (right).
The final volume of the reaction was 10 μl, and a Light-
Cycler instrument was used to perform the PCR reac-
tion (Roche Diagnostic). The following PCR conditions
were used: 10 minutes at 95°C, followed by 40 cycles of
10 seconds at 95°C, 30 seconds at 60°C, and 1 second at
72°C and 1 cycle cooled for 30 seconds at 40°C. The
samples were normalised to the b-actin gene. The rela-
tive expression of the PRL receptor was calculated using
the 2ΔCT formula.
Induction of hyperprolactinaemia
Groups of 14 female, 9-week-old C57BL/6 and MRL/lpr
mice and 7 female MRL mice were given a daily subcu-
taneous injection of 100 μg of metoclopramide (Sigma
Aldrich, St Louis MO, USA) in 100 μlo fP B Sf o rs i x
weeks. A matched control group (C57BL/6, MRL and
MRL/lpr) received only PBS (100 μl) over the same per-
iod. Urinary protein levels were assessed semiquantita-
tively using reagent strips for urinalysis (Uri-Quick
Stanbio Laboratory, KendallT X ,U S A ) .S e r u ms a m p l e s
were obtained at the beginning and at the end of the
experiments, between 08:00 and 11:00 hours, and kept
at -35°C until assayed for prolactin and anti-DNA
antibodies.
Prolactin assessment
Serum levels of prolactin were detected using ELISA.
The 96-well maxisorp plates (Nunc, Rochester NY,
USA) were coated overnight with 100 μlo f4μg/ml
anti-mouse prolactin monoclonal antibody (clone
207518, R&D Systems, Minneapolis MN, USA) in PBS
at 4°C, blocked with 2% bovine serum albumin (Invitro-
gen, Carlsbad CA, USA), and incubated with the serum
sample (1:10) overnight at 4°C. Recombinant mouse
prolactin (National Hormone and Peptide Program,
NIH, donated by AF Parlow) was used as a standard.
The plates were then incubated with 0.1 μg/ml biotiny-
lated anti-prolactin antibody (R & D Systems, Minnea-
polis MN, USA), avidin-alkaline phosphatase (Zymed
Laboratories, San Francisco CA, USA) and 5-bromo-4-
chloro-3 indolyl phosphate (Sigma-Aldrich, St Louis
MO, USA) as a substrate, according to the manufac-
turer’s instructions. The OD was monitored at 405 nm
using a Dynatech MR5000 ELISA reader.
Determination of anti-DNA antibodies
Anti-dsDNA antibody serum concentrations were
detected using ELISA. A 96-well maxisorp plate (Nunc,
Rochester NY, USA) was coated with 100 μlo f2 . 5μg/ml
calf thymus dsDNA (Sigma Aldrich, St Louis MO, USA)
in bicarbonate buffer overnight at 4°C and was blocked
with 2% bovine serum albumin (Invitrogen, Carlsbad CA,
USA). The plates were then incubated for 1 h at 37°C
with serum (1:50) or the anti-dsDNA antibody standard
(clone 16-13, Chemicon International, Billerica MA,
USA), followed by rabbit anti-mouse IgG, IgG1, IgG2a or
anti-mouse IgM conjugated to alkaline phosphatase
(Zymed Laboratories, San Francisco CA, USA) and sub-
strate ([5-bromo-4-chloro-3- indolyl phosphate; Sigma-
Aldrich, St Louis MO, USA]). The OD was monitored at
405 nm using a Dynatech MR5000 ELISA reader.
Cell surface staining and flow cytometry
Splenocytes were incubated with fluorescently labelled
antibodies for 20 minutes at 4°C in staining buffer (PBS
with 0.5% BSA and 0.01% sodium azide). The cells were
then washed and fixed in 2% paraformaldehyde (Sigma
Aldrich, St Louis MO, USA). The data were acquired using
a FACSAria flow cytometer (BD Bioscience) and analysed
with FlowJo software (Tree Star, Ashland OR, USA).
Statistical analysis
T h ed a t aw e r ea n a l y s e dw i t hs t a n d a r ds t a t i s t i c a lt e s t s
(mean value, SD, Student’s t test, and ANOVA), and the
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Page 12 of 14results are expressed as the mean ± SD. The level of sig-
nificance was set at p ≤ 0.05. All calculations were per-
formed using SPSS 15 software.
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